European Urology Oncology

Slides:



Advertisements
Similar presentations
The future perspectives in transrectal prostate ultrasound guided biopsy Sung Il Hwang, Hak Jong Lee Prostate International Volume 2, Issue 4, Pages
Advertisements

Clinical Nutrition ESPEN
Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness.
Cost-effectiveness of culture-guided antimicrobial prophylaxis for the prevention of infections after prostate biopsy  Chi-kong Li, Brian C.Y. Tong, Joyce.
Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.
Volume 71, Issue 6, Pages (June 2017)
Volume 69, Issue 3, Pages (March 2016)
Volume 15, Issue 2, Pages (March 2012)
Markov model structure
Value in Health Regional Issues
Volume 56, Issue 6, Pages (December 2009)
Volume 72, Issue 6, Pages (December 2017)
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.
European Urology Oncology
Volume 65, Issue 6, Pages (June 2014)
Volume 66, Issue 1, Pages (July 2014)
Volume 69, Issue 3, Pages (March 2016)
Towards Early and More Specific Diagnosis of Prostate Cancer
Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.
Prostate Cancer Detection: A View of the Future
Volume 67, Issue 4, Pages (April 2015)
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Volume 72, Issue 6, Pages (December 2017)
Volume 65, Issue 6, Pages (June 2014)
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 68, Issue 4, Pages (October 2015)
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria.
Volume 67, Issue 6, Pages (June 2015)
Volume 68, Issue 6, Pages (December 2015)
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Volume 66, Issue 3, Pages (September 2014)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
European Urology Oncology
European Urology Oncology
European Urology Oncology
Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study  Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,
European Urology Oncology
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Value in Health Regional Issues
Volume 73, Issue 1, Pages (January 2018)
European Urology Oncology
Volume 152, Issue 1, Pages (January 2019)
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Volume 65, Issue 3, Pages (March 2014)
Volume 75, Issue 4, Pages (April 2019)
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review  Alexey Surov, Hans Jonas Meyer, Andreas.
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis  Joseph Sargon Joseph, Vincent.
The Cost to Medicare of Bladder Cancer Care
European Urology Oncology
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
European Urology Oncology
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.
European Urology Oncology
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.
Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer  Thibaut Lizée, MD, Ethan Basch, MD, MSc, Pierre Trémolières,
European Urology Oncology
Salvage Local Treatments After Focal Therapy for Prostate Cancer
European Urology Oncology
European Urology Oncology
Probabilistic sensitivity analysis.
European Urology Oncology
Cost-effectiveness acceptability curves (CEAC) of tight control versus clinical management excluding (base case) and including absenteeism due to Crohn’s.
Maximilian Burger, Ashish M. Kamat, David McConkey 
Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood  Jan F.M. Verbeek,
Lars Oddershede, MMS, Jan J. Andreasen, MD, PhD, Barbara C
European Urology Oncology
Presentation transcript:

European Urology Oncology The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study  Sejal Patel, Jan J. Rongen, Jurgen J. Fütterer, Artem Boltyenkov, Maroeska M. Rovers  European Urology Oncology  DOI: 10.1016/j.euo.2018.05.007 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Markov model. PCa=prostate cancer. European Urology Oncology DOI: (10.1016/j.euo.2018.05.007) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Scatter plots of probabilistic sensitivity analyses. (A) Scatter plot of probabilistic sensitivity analysis for multiparametric magnetic resonance imaging (mpMRI) with biopsy versus transrectal ultrasound-guided biopsy (TRUSGB) including a summary point that represents the overall estimate of the incremental cost-effectiveness ratio (ICER) over the 10 000 iterations. At a willingness to pay (WTP) of €50 000 per quality-adjusted life year (QALY), mpMRI with biopsy was cost-effective in 90% of the iterations. (B) Scatter plot of probabilistic sensitivity analysis for mpMRI only versus TRUSGB including a summary point that represents the overall estimate of the ICER over the 10 000 iterations. At WTP of €50 000 per QALY, mpMRI only was cost-effective in 14% of the iterations. (C) Scatter plot of probabilistic sensitivity analysis with the results reported by Ahmed et al [28] for mpMRI with biopsy versus TRUSGB, including a summary point that represents the overall estimate of the ICER over the 10 000 iterations. At WTP of €50 000 per QALY, mpMRI with biopsy was cost-effective in 97% of the iterations. (D) Scatter plot of probabilistic sensitivity analysis for the results reported by Ahmed et al [28] for mpMRI only versus TRUSGB, including a summary points that represents the overall estimate of the ICER over the 10 000 iterations. At WTP of €50 000 per QALY, mpMRI only was cost-effective in 17% of the iterations. European Urology Oncology DOI: (10.1016/j.euo.2018.05.007) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Deterministic sensitivity analyses. (A) Tornado plot (deterministic one-way sensitivity analysis). (B) Deterministic two-way sensitivity analysis at a willingness to pay of €50 000 per quality-adjusted life year. TRUSGB=transrectal ultrasound-guided biopsy; mpMRI=multiparametric magnetic resonance imaging; MR-TRUSGB=magnetic resonance TRUSGB; AS=active surveillance. European Urology Oncology DOI: (10.1016/j.euo.2018.05.007) Copyright © 2018 European Association of Urology Terms and Conditions